Predicting survival in pancreatic cancer using the HELPP score

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to validate the HELPP score, a preoperative prognostic tool designed to predict survival outcomes in patients with localized non-metastatic pancreatic ductal adenocarcinoma. The study will assess the HELPP score's ability to forecast median overall survival and recurrence-free survival in a prospective multi-institutional cohort. By utilizing routinely available laboratory biomarkers and clinical data, the HELPP score seeks to improve the accuracy of pre-treatment staging and prognosis. The study will include all consecutive patients undergoing exploration for potential resection within a 12-month timeframe.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old
* fit to undergo elective pancreatic resection or palliative therapy
* localized non-metastatic pancreatic ductal adenocarcinoma
* informed consent provided

Exclusion Criteria:

* patients with a diagnosis other than pancreatic ductal adenocarcinoma on histopathology
* missing informed consent
* missing mandatory pretreatment laboratory values
* missing mandatory pretreatment clinicopathologic data
* patients receiving surgery for peripancreatic cancer
* incomplete follow-up records
* follow-up \< 24 months
* pregnancy

Where it's running

• Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna
  Vienna, Austria Recruiting

Study contacts

• Study coordinator: Carl Leonhardt, MD MBA
• Email: carl-stephan.leonhardt@meduniwien.ac.at
• Phone: +43140400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• MyCap app to track time burden of pancreatic cancer treatment

  This study tests whether a mobile app can help adults with pancreatic cancer log the time they spend on cancer care.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07619391

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

• Lorigerlimab in pancreatic cancer with BRCA/RAD51 gene mutations

  This phase 2 study tests Lorigerlimab in adults with metastatic pancreatic cancer who have BRCA1/2, PALB2, RAD51C, or RAD51D germline mutations.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07565155

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.